The latest Phase III data on Verrica’s formulation of cantharidin for the skin disease molluscum show a wider disparity from placebo.
Verrica Pharmaceuticals Inc. aims to have the first FDA-approved drug therapy for molluscum contagiosum with a product that offers greater stability compared to compounded cantharidin, a quick on set of action and convenient application.
The Philadelphia-area firm presented full data from its pivotal Phase III CAMP-1 and CAMP-2 studies of VP-102 at the American
The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.
InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.
